Commercial StrategyCommercial preparation for a potential US launch is already underway, with Biohaven building a commercialization team and targeting high-volume treatment centers and COEs.
Market OpportunityThere are currently no FDA-approved therapies for spinocerebellar ataxia, which suggests a significant market opportunity for troriluzole upon approval.
Regulatory ProcessThe FDA's Division of Neurology I no longer requires an advisory committee meeting for regulatory decision-making regarding the NDA for troriluzole in spinocerebellar ataxia.